Pascal Biosciences Announces Formation of Clinical Advisory Board
Preeminent Neuro-Oncology Experts to Guide PAS-403 Development Efforts
VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, May 8, 2019 – Pascal Biosciences Inc. (TSX.V:PAS)(“Pascal” or the “Company”), a drug discovery and development company, today announced it has formed a clinical advisory board (“CAB”) of preeminent neuro-oncology experts to guide its PAS-403 therapeutic program. PAS-403 is Pascal’s clinical candidate for the treatment of glioblastoma, a devastating brain cancer with limited therapeutic options.
“We are extremely fortunate to have assembled this world-renowned group of leading researchers and clinicians in the field of neuro-oncology,” said Dr. Patrick Gray, CEO of Pascal. “Their knowledge and insights will guide our PAS-403 program for the treatment of glioblastoma. Only three treatments have been approved in the last 30 years for glioblastoma. After reviewing our data, our CAB has strongly encouraged us to proceed with PAS-403 clinical trials to make advancements for this devastating disease.”
Members of the clinical advisory board include:
- Chair: Dr. Darell Bigner – E.L. and Lucille F. Jones Cancer Research Professor, Duke University School of Medicine
Dr. Bigner is founding Director of the Preston Robert Tisch Brain Tumor Center. His research has involved the investigation of the causes, mechanism of transformation, altered growth control, and development of new methods of therapy for primary brain tumors and those metastasizing to the brain. Dr. Bigner has over 600 scientific publications and received the Lifetime Achievement Award from the Society of Neuro-Oncology in 2014.
- Mitchell Berger – Professor and Chair, Neurological Surgery, University of California, San Francisco
Dr. Berger is an internationally recognized expert in treating brain and spinal cord tumors in adults and children. He is co-director of the Adult Brain Tumor Surgery Program, director of the Brain Tumor Research Center and director of the Center for Neurological Injury and Repair. Dr. Berger is a past-president of the Society for Neuro-Oncology (1997-1999), has received the Victor Levin Award in Neuro-oncology Researchfrom the Society of Neuro-Oncology in 2015, was named on the Blue Ribbon Panel of scientific experts for the National Cancer Moonshot Initiative, and has also served as president of the American Association of Neurological Surgeons.
- Timothy Cloughesy –Professor of Neurology, University of California, Los Angeles
Dr. Cloughesy is Director of the UCLA Neuro-Oncology program. Dr. Cloughesy’s research focuses on clinical trials in brain cancer using targeted molecular therapies with novel clinical trial design. He has developed a brain cancer bioinformatics database which combines clinical outcomes, imaging and molecular analysis to enhance translational research. For more than a decade, he has been recognized as both a Top Doctor and Top Doctor for Cancer by U.S. News.
- Patrick Wen –Professor of Neurology, Harvard Medical School
Dr. Wen is Director of the Center for Neuro-Oncology, Dana Farber Cancer Research Institute and Director of the Division of Cancer Neurology at Brigham and Women’s Hospital. Dr. Wen’s research is focused on novel treatments of brain tumors, especially targeted molecular agents, and optimizing response assessment and clinical trial endpoints in neuro-oncology. He currently serves as President of the Society of Neuro-Oncology, the premier North American organization for health care professionals focusing on central nervous system tumors in children and adults.
- Andrew Sloan – Professor, Departments of Neurological Surgery and of Pathology, School of Medicine, Case Western Reserve University
Dr. Sloan serves as Director of the Brain Tumor and Neuro-Oncology Center at the Seidman Cancer Center and is also Vice Chairman of Neurosurgery at University Hospitals Cleveland Medical Center.His clinical and research interests focus on the biology and treatment of tumors of the brain and spine.He has been recognized by his peers as one of the “Best Doctors in America” since 2003, and as one of the “Top Surgeons in America” since 2007. In 2014, he was elected President of the Ohio State Neurosurgical Society.
Pascal has demonstrated that PAS-403 is active against human glioblastoma cells in cell culture, accumulates in the brain, has a good safety profile, and displays striking synergy with standard of care in an animal model of glioblastoma. With input from our CAB, a clinical plan is being developed for testing PAS-403 in glioblastoma patients.
About Pascal Biosciences Inc.
Pascal is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The Company’s leading portfolio comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy. In addition, Pascal is developing a B-cell targeted antibody for acute lymphoblastic leukemia. For more information, visit www.pascalbiosciences.com.
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.
“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”